The long term objective is to develop a new technology for industry scale affinity separations employing proprietary Bio-Receptor ferrofluids (BR-FF) in combination with existing continuous high gradient magnetic separators (HGMS) and improved systems currently being developed. BR-FF are being used with HGMS successfully for doing immunoassays and together they represent a significant step forward in the field offering numerous advantages over prior systems.
The specific aims of this proposal are to determine if BR-FF as currently synthesized or as synthesized by relatively straightforward modification can withstand the rigors of desorption (low pH, denaturants, Kaotropic ions) and recycling. Affinity separations currently play a minor role in bioprocessing in part because of cost and the nature of affinity supports (particles or membranes) which are constrained to batch mode and ultra clean solutions. BR-FF and HGMS offers the potential for continuous affinity separation which can function in the presence of major solution contaminents including solids; thus a new bioprocessing technology which also requires significantly less processing steps is possible.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL046073-01
Application #
3501975
Study Section
Special Emphasis Panel (SSS (B2))
Project Start
1991-04-15
Project End
1991-10-14
Budget Start
1991-04-15
Budget End
1991-10-14
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Immunicon Corporation
Department
Type
DUNS #
City
Huntingdon Valley
State
PA
Country
United States
Zip Code
19006